Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism

Ding, Jie; Zhang, Yushi; Wen, Ji; Zhang, Hui; Wang, Huiping; Luo, Yaping; Pan, Qingqing; Zhu, Wenjia; Wang, Xuezhu; Yao, Shaobo; Kreißl, Michael C.; Hacker, Marcus; Tong, Anli; Huo, Li; Li, Xiang

doi:10.1007/s00259-020-04722-0

Cited by 54 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this pilot study, we evaluated the performance of 68 Ga-pentixafor PET/CT imaging for the functional lateralization of adrenal lesions and its effectiveness in identifying functional adrenal adenomas to help guide management decisions. The initial finding for APA lesions detection in patients with PA was reported pioneeringly (10). In the present study, we furtherly included 28 patients (including 22 PA, 1 NFA, 3 CS and 2 PCC patients) with relatively heterogeneous adrenal tumour types, which was an extension from the previous reports and provided complementary evidence for potential implementation of adrenal benign mass screening by 68 Ga-pentixafor PET/CT.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose:We aimed to investigate the diagnostic and prognostic value of 68 Ga-pentixafor positron emission tomography (PET)/computed tomography (CT) imaging in non-cancer patients with suspected adrenal masses.Methods: Sixty-four patients who had benign adrenal masses on CT were retrospectively included in our study. All patients underwent 68 Ga-pentixafor PET/CT scans, and 56 of these patients subsequently underwent adrenalectomy. The subtypes of 81 adrenal tumors including 14 nonfunctioning adrenal nodules, 4 cortisol-producing adenomas, 41 aldosterone-producing adenomas, 5 suspected unilateral adrenal hyperplasia, 15 idiopathic aldosterone hyperplasia and 2 pheochromocytomas, were determined by histology or follow-up evaluations. The functional lateralization diagnosis efficiency was calculated by visual analysis. Semiquantitative parameters of these lesions including maximum standardized uptake value (SUVmax), the ratio of lesional SUVmax to normal liver SUVmean (LLR), and the ratio of lesional SUVmax to contralateral adrenal tissue SUVmean (LCR) have also been calculated. Dynamic analysis has also been performed on fifteen patients. Besides, clinical outcomes were assessed and compared in patients who underwent adrenalectomy. Results:The sensitivity and specificity of 68 Ga-pentixafor PET for functional lateralization of patients with adrenocortical lesions were 97.8% (45/46) and 87.5% (14/16) respectively. The two pheochromocytoma lesions had lower pentixafor uptake compared to the normal adrenal glands. Functioning (active) adrenocortical adenomas showed an elevated SUVmax of 16.3±7.9 4 in comparison to 4.4±1.7 in nonfunctioning (inactive) adenomas and 5.5±2.7 in hyperplasia lesions (P<0.0001). To identify active adrenocortical adenomas, a cutoff value of 7.1 for SUVmax showed a sensitivity of 90.9% and a specificity of 85.3% (AUC=0.96, P<0.0001); a cutoff value of 2.5 for LLR showed a sensitivity of 95.5% and a specificity of 88.2% (AUC=0.97, P<0.0001); and a cutoff value of 2.4 for LCR showed a sensitivity of 88.6% and a specificity of 91.8% (AUC=0.95, P<0.0001). The graphical Ki of active adrenocortical adenomas was significantly higher than in-active adenomas. Uptake values for 68 Ga-pentixafor were significantly higher in patients with preferable outcomes (cured/improved) (SUVmax=15.5±8.0, LLR=6.5±4.3, LCR=6.2±5.0) than in patients with nonpreferable outcomes (no improvement) (SUVmax=4.2±0.5, LLR=1.3±0.2, LCR =1.5±0.6, all P<0.0001). Conclusion:68 Ga-pentixafor PET/CT imaging exhibits great potential for noninvasive functional lateralization and characterization of patients with adrenocortical masses.

show abstract

Section: Discussionmentioning

confidence: 87%

“…The preparation of 68 Ga-pentixafor was conducted as has previously been described (10), with a radiochemical purity of at least 95%. All images were acquired using a dedicated PET/CT scanner (PoleStar m660; SinoUnion Healthcare Inc., Beijing, China) at the Peking Union Medical College Hospital.…”

Section: Static and Dynamic Pet Imagingmentioning

confidence: 99%

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Over the last decade, tremendous progress has been made in the development of novel radiopharmaceuticals by a large number of universities, hospitals, and research institutions in China. Numerous publications in this topic have become available in the literature, including a recent manuscript in Nature [17] and increasing number of publications in EJN-MMI [18][19][20][21][22][23][24]. The trajectory has displayed a major upward trend over the last decade, which clearly showed that this is a highly vibrant field.…”

Section: Research and Development Of Radiopharmaceuticalsmentioning

confidence: 99%

Current status and future perspective of radiopharmaceuticals in China

Ji¹,

Li²,

Sui³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Interestingly, CXCR4 expression is almost negligible in nonfunctioning adenomas on immunohistochemical studies (24). In a prospective study that included 36 patients with PHA, 68 Ga-pentixafor was effective in distinguishing aldosteroneproducing adenoma from nonfunctioning adenoma and hyperplasia (25). On immunohistochemistry analysis, 24 of 25 aldosteroneproducing adenoma showed an intense CXCR4 expression, whereas the remaining lesions (4 hyperplasia and 5 nonfunctioning adenoma) did not express (5/11) or slightly expressed (6/11) CXCR4.…”

Section: Second Step: Distinguish the Clinical Scenariosmentioning

confidence: 99%

A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses

et al. 2021

View full text Add to dashboard Cite

Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism

Cited by 54 publications

References 21 publications

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor

Current status and future perspective of radiopharmaceuticals in China

A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses

Contact Info

Product

Resources

About

Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism

Cited by 54 publications

References 21 publications

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor

Current status and future perspective of radiopharmaceuticals in China

A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses

Contact Info

Product

Resources

About

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor